Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Amortizatization of Intangibles: 2020-2025

Historic Amortizatization of Intangibles for Fulcrum Therapeutics (FULC) over the last 6 years, with Sep 2025 value amounting to $586,000.

  • Fulcrum Therapeutics' Amortizatization of Intangibles fell 49.13% to $586,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 26.39%. This contributed to the annual value of $4.4 million for FY2024, which is 26.69% down from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Amortizatization of Intangibles stood at $586,000, which was down 45.99% from $1.1 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Amortizatization of Intangibles high stood at $1.7 million for Q2 2023, and its period low was -$386,000 during Q4 2021.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $1.2 million (2024), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Amortizatization of Intangibles slumped by 1,002.86% in 2021, and later surged by 1,515.18% in 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Amortizatization of Intangibles (Quarterly) stood at -$386,000 in 2021, then skyrocketed by 255.70% to $601,000 in 2022, then skyrocketed by 120.97% to $1.3 million in 2023, then decreased by 28.84% to $945,000 in 2024, then plummeted by 49.13% to $586,000 in 2025.
  • Its Amortizatization of Intangibles was $586,000 in Q3 2025, compared to $1.1 million in Q2 2025 and $899,000 in Q1 2025.